Hexavalent Vaccines in India: Current Status

被引:7
作者
Chitkara, Amar Jeet [1 ]
Parikh, Raunak [2 ]
Mihalyi, Attila [3 ]
Kolhapure, Shafi [2 ]
机构
[1] Max Superspecial Hosp, Dept Pediat, Delhi, India
[2] Glaxo Smith Kline Biol SA, Mumbai, Maharashtra, India
[3] Glaxo Smith Kline Biol SA, Wavre, Belgium
关键词
Combination vaccines; Acellular Vaccine; Immunization; Pertussis; PNEUMOCOCCAL CONJUGATE VACCINE; ACELLULAR PERTUSSIS-VACCINE; 3-DOSE PRIMARY VACCINATION; DTPA-HBV-IPV/HIB; ROUTINE INFANT; B VACCINE; COMBINATION VACCINES; IMMUNOGENICITY; SAFETY; IMMUNIZATION;
D O I
10.1007/s13312-019-1651-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Hexavalent vaccines containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, poliomyelitis, and hepatitis B virus antigens have the potential to be used for the primary series in India (6, 10, 14 weeks of age) and the toddler booster dose. Three hexavalent vaccines are available in India: DTwP-Hib/HepB-IPV (wP-hexa), DTaP-IPV-HB-PRPT(2aP-hexa), and DTaP-HBV-IPV/Hib (3aP-hexa). In the three published phase-3 Indian studies, pertussis 'vaccine response' rates 1 month after a 6-10-14-week primary series were 68.4-75.7% for wP-hexa, 93.8-99.3% for 2aP-hexa, and 97.0-100% for 3aP-hexa; seroprotection rates for the other five antigens were 88.2-100%, 49.6-100%, and 98.6-100%, respectively. Studies outside India show: good immunogenicity/safety after boosting dosing; immune persistence to age 4.5 years (2aP-hexa), 7-9 years (3aP-hexa) (all antigens), and 9-10 and 14-15 years, respectively (hepatitis B); and successful co-administration with other vaccines. Hexavalent vaccines could reduce the number of injections, simplify vaccination schedules, and improve compliance.
引用
收藏
页码:939 / 950
页数:12
相关论文
共 65 条
[1]  
[Anonymous], 2017, Wkly Epidemiol Rec, V92, P53
[2]  
[Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
[3]  
[Anonymous], 2013, Wkly Epidemiol Rec, V88, P413
[4]  
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[5]  
[Anonymous], 2019, CURR UIP SCHED
[6]   Global Polio Eradication - Way Ahead [J].
Bahl, Sunil ;
Bhatnagar, Pankaj ;
Sutter, Roland W. ;
Roesel, Sigrun ;
Zaffran, Michel .
INDIAN JOURNAL OF PEDIATRICS, 2018, 85 (02) :124-131
[7]   Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years [J].
Balasubramanian, S. ;
Shah, Abhay ;
Pemde, Harish K. ;
Chatterjee, Pallab ;
Shivananda, S. ;
Guduru, Vijay Kumar ;
Soans, Santosh ;
Shastri, Digant ;
Kumar, Remesh .
INDIAN PEDIATRICS, 2018, 55 (12) :1066-1074
[8]   The pertussis enigma: reconciling epidemiology, immunology and evolution [J].
de Celles, Matthieu Domenech ;
Magpantay, Felicia M. G. ;
King, Aaron A. ;
Rohani, Pejman .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2016, 283 (1822)
[9]   Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants [J].
Chhatwal, Jugesh ;
Lalwani, Sanjay ;
Vidor, Emmanuel .
INDIAN PEDIATRICS, 2017, 54 (01) :15-20
[10]   Pertussis outbreaks in the developed world: Are acellular pertussis vaccines ineffective? [J].
Chitkara, A. J. ;
Vashistha, Vipin M. .
INDIAN PEDIATRICS, 2013, 50 (12) :1109-1112